Biofrontera Inc. (BFRI:NSD) Benchmark and Roth Capital see gigantic upside

Based on the Biofrontera Inc stock (bfri stock price) forecasts from 2 analysts, the average analyst target price for Biofrontera Inc (bfri stock price) is $15.50 over the next 12 months. Biofrontera Inc’s average analyst rating is a Buy. Stock Target Advisor’s own stock analysis of Biofrontera Inc is Very Bearish, which is based on 0 positive signals and 4 negative signals. At the last closing, Biofrontera Inc’s stock price was USD 1.99. Biofrontera Inc’s stock price has changed by -0.10% over the past week, -0.89% over the past month and +0.00% over the last year.

In the United States, the biopharmaceutical company Biofrontera Inc. commercialises pharmaceuticals for the treatment of dermatological diseases. The company offers the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp, as well as Ameluz, a prescription medication approved for use in conjunction with the company’s licensor’s medical device. Additionally, it contains the prescription cream Xepi for impetigo therapy. The business was founded in 2015, and its main office is in Woburn, Massachusetts.


What we like:

There is no fundamental attribute that we can detect on the stock that would warrant a positive outlook. The stock is a pure speculative play!

What we don’t like:

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector